Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2020



Schrödinger, Inc.

(Exact name of Registrant as Specified in Its Charter)




Delaware     95-4284541

(State or other jurisdiction of

incorporation or organization)



(Commission File Number)

  (I.R.S. Employer
Identification No.)

120 West 45th Street, 17th Floor

New York, NY

(Address of principal executive offices)     (Zip Code)

Registrant’s telephone number, including area code: (212) 295-5800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class   



   Name of each exchange on which registered






Common stock, par value $0.01 per share    SDGR    The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 2.02

Results of Operations and Financial Condition.

On May 13, 2020, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits:






99.1    Press release issued dated May 13, 2020





Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



Schrödinger, Inc.

Date: May 13, 2020     By:   /S/ JOEL LEBOWITZ
      Joel Lebowitz

Chief Financial Officer

(Principal Financial Officer)





Exhibit 99.1

Schrödinger Reports First Quarter 2020 Financial Results and Recent Business Updates

Total revenue of $26.2 million and strong growth of 26% year-over-year

Record software revenue of $23.8 million, up 28% year-over-year

Raised $209.6 million in net proceeds through initial public offering

Conference call today, Wednesday, May 13, 2020 at 8:30 a.m. ET

NEW YORK – May 13, 2020 - Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced financial results for the first quarter ended March 31, 2020.

“The first quarter was marked by a significant milestone for Schrödinger with the completion of our successful IPO, which is a credit to our employees and our commitment to advancing the science underlying our platform,” said Schrödinger CEO Ramy Farid, Ph.D. “We are proud of what our team has accomplished, and we will continue to innovate as we work towards our mission of improving human health and quality of life by transforming the way therapeutics and materials are discovered.”

First Quarter Financial Results

Revenue was $26.2 million for the first quarter of 2020, a year-over-year increase of 26%.

Software revenue was $23.8 million for the quarter, representing a 28% increase from the first quarter of 2019. Drug discovery revenue was $2.4 million for the quarter, representing an 11% increase from the first quarter of 2019.

Gross profit reached $15.6 million in the first quarter versus $13.0 million in the first quarter of 2019. Software gross margin in the first quarter was 83%, unchanged from the first quarter of 2019.

Operating expenses for the first quarter of 2020 were $27.4 million, representing an increase of 47% from the first quarter of 2019.

Net loss, after adjusting for non-controlling interests, was $13.8 million, compared to $5.8 million in the same period in 2019.

Schrödinger ended the first quarter with cash, cash equivalents, restricted cash and marketable securities of $288.8 million.

“We are very pleased with our performance in the first quarter of 2020. Our revenue growth reflects the continuing trend of increased adoption of our physics-based solutions by pharmaceutical, biotechnology, and industrial companies,” said Schrödinger CFO Joel Lebowitz. “This quarter we also continued to invest heavily in research and development to advance our wholly-owned programs and the science underlying our platform.”

First Quarter & Recent Business Updates

Advancing the underlying computational platform. Schrödinger released new software capabilities to expand the domain of applicability of its technology and improve upon the accuracy of its methods. This includes a next-generation version of its protein refinement software package and advances in ADME/Tox property predictions.

Progressing internal drug discovery programs, including Wee1 kinase inhibitor and MALT1 inhibitor. Schrödinger expects to begin the nomination of development candidates in its wholly-owned pipeline for preclinical development by the end of 2020 and initiate IND-enabling studies by the first half of 2021. “Our integrated drug discovery teams have been able to continue advancing the programs by leveraging our computational platform, which allows for large-scale evaluation of molecules with significantly reduced reliance on wet lab experiments,” said Karen Akinsanya, Ph.D., Chief Biomedical Scientist and Head of Discovery R&D. “Further, despite the challenges of COVID-19, our global network of CROs has continued to support the progress of these programs with minimal delays.”

Expanding an existing collaboration with AstraZeneca to focus on refining a biologics modeling solution. In March, Schrödinger announced an expanded collaboration with AstraZeneca with the aim of accelerating the development of antibody and protein-based therapeutic candidates by enhancing Schrödinger’s free energy perturbation technology (FEP+) for the optimization of key properties of biologics, such as affinity and selectivity.

COVID-19 business impact. “While we did not see material impacts to our business during the first quarter, certain market risks are beginning to emerge that could affect our software growth and the timing of our drug discovery revenues in 2020. Some customers may experience budget pressures and potentially delay purchases, or our sales could be impacted by our inability to engage with customers in person. The crisis could also delay the progress of certain collaboration programs, particularly ones that are in clinical studies or preparing to enter clinical studies,” Mr. Lebowitz said. “We view these risks as temporary, and we believe we have ample resources to manage our business effectively during this time. We do not envision a long-term impact on our ability to execute on our strategy.”

Joining alliance to combat COVID-19. Schrödinger has joined a multi-company philanthropic effort to discover and develop novel small-molecule antiviral therapeutics to address COVID-19. The intent of the alliance, which to date also includes Takeda, Novartis, Gilead, and WuXi AppTec, is to make any discoveries from this alliance available to the public. There is no expectation that this effort will generate revenue for any of the companies involved in the alliance, including Schrödinger.



“We are proud to be involved in this alliance and hopeful the alliance will contribute meaningfully to addressing this global health crisis,” Dr. Farid said.

Webcast and Conference Call Information

Schrödinger will host a conference call to discuss its first quarter financial results on Wednesday, May 13, 2020 at 8:30 a.m. EDT. The conference call can be accessed live over the phone by dialing (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and refer to conference ID 2783269. The webcast can be accessed under “News & Events” in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. The archived webcast will be available on Schrödinger’s website following the event.

About Schrödinger

Schrödinger’s industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. Schrödinger is also applying its computational platform to a diverse and extensive pipeline of drug discovery programs in collaboration with pharmaceutical companies and has co-founded leading biotech companies. In addition, Schrödinger is using its platform to advance a pipeline of internal, wholly-owned drug discovery programs.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding our expectations about the speed and capacity of our computational platform, our plans to continue to invest in research and our strategic plans to accelerate the growth of our software business and advance our collaborative and internal drug discovery programs, our expectations related to the use of our cash, cash equivalents, and marketable securities as well as our expectations related to the COVID-19 pandemic’s impact on our business. Statements including words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the demand for our software solutions, our ability to further develop our computational platform, our reliance upon third-party providers of cloud-based infrastructure to host our software solutions, our reliance upon our third-party drug discovery



collaborators, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business and other risks detailed under the caption “Risk Factors” and elsewhere in our Securities and Exchange Commission filings and reports, including the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2020, as well as future filings and reports by us, including our Quarterly Report on Form 10-Q for the quarter ending March 31, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.

Media Contact:

Stephanie Simon

Ten Bridge Communications



Investor Contact:

Christina Tartaglia

Stern IR, Inc.





Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except for share and per share amounts)


Assets    March 31, 2020     December 31, 2019  

Current assets:


Cash and cash equivalents

   $ 144,749     $ 25,986  

Restricted cash

     500       500  

Marketable securities

     143,505       59,844  

Accounts receivable, net of allowance for doubtful accounts of $50 and $50

     16,272       18,676  

Unbilled and other receivables

     1,908       7,062  

Prepaid expenses

     5,881       6,468  







Total current assets

     312,815       118,536  

Property and equipment, net

     6,488       6,268  

Equity investments

     15,156       15,366  

Right of use assets

     13,241       12,762  

Other assets

     2,172       2,338  







Total assets

   $ 349,872     $ 155,270  






Liabilities, Convertible Preferred Stock, and Stockholders’ Equity (Deficit)             

Current liabilities:


Accounts payable

   $ 6,675     $ 3,524  

Accrued payroll, taxes, and benefits

     4,745       7,034  

Deferred revenue

     21,710       25,054  

Lease liabilities

     5,851       5,584  

Other accrued liabilities

     3,185       3,824  







Total current liabilities

     42,166       45,020  

Deferred revenue, long-term

     2,125       2,205  

Lease liabilities, long-term

     9,133       8,888  

Other liabilities, long-term

     900       900  







Total liabilities

     54,324       57,013  







Commitments and contingencies (Note 4)


Convertible preferred stock:


Series E convertible preferred stock, $0.01 par value. Authorized zero and 77,150,132 shares; zero and 73,795,777 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

     —         109,270  

Series D convertible preferred stock, $0.01 par value. Authorized zero and 39,540,611 shares; zero and 39,540,611 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

     —         22,000  

Series C convertible preferred stock, $0.01 par value. Authorized zero and 47,242,235 shares; zero and 47,242,235 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

     —         19,844  

Series B convertible preferred stock, $0.01 par value. Authorized zero and 29,468,101 shares; zero and 29,468,101 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

     —         9,840  

Series A convertible preferred stock, $0.01 par value. Authorized zero and 134,704,785 shares; zero and 134,704,785 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

     —         30,626  







Total convertible preferred stock

     —         191,580  







Stockholders’ equity (deficit):


Common stock, $0.01 par value. Authorized 500,000,000 and 425,000,000 shares; 50,122,938 and 6,121,821 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

     501       61  

Limited common stock, $0.01 par value. Authorized 100,000,000 and 146,199,885 shares; 13,164,193 and zero shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

     132       —    

Additional paid-in capital

     414,248       11,655  

Accumulated deficit

     (118,922     (105,096

Accumulated other comprehensive (loss) income

     (442     16  







Total stockholders’ equity (deficit) of Schrödinger stockholders

     295,517       (93,364

Noncontrolling interest

     31       41  







Total stockholders’ equity (deficit)

     295,548       (93,323







Total liabilities, convertible preferred stock, and stockholders’ equity (deficit)

   $ 349,872     $ 155,270  









Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except for share and per share amounts)


     Three Months Ended March 31,  
     2020     2019  



Software products and services

   $ 23,812     $ 18,605  

Drug discovery

     2,362       2,136  







Total revenues

     26,174       20,741  







Cost of revenues:


Software products and services

     4,001       3,133  

Drug discovery

     6,548       4,604  







Total cost of revenues

     10,549       7,737  







Gross profit

     15,625       13,004  







Operating expenses:


Research and development

     13,700       8,438  

Sales and marketing

     4,789       5,093  

General and administrative

     8,936       5,086  







Total operating expenses

     27,425       18,617  







Loss from operations

     (11,800     (5,613







Other (expense) income:


Change in fair value

     (3,079     (627

Interest income

     699       438  







Total other expense

     (2,380     (189







Loss before income taxes

     (14,180     (5,802

Income tax expense

     91       46  







Net loss

     (14,271     (5,848

Net loss attributable to noncontrolling interest

     (445     (54







Net loss attributable to Schrödinger common and limited common stockholders

   $ (13,826   $ (5,794







Net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted:

   $ (0.34   $ (0.98

Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted:

     40,666,970       5,938,260  



Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)


     Three Months Ended March 31,  
     2020     2019  

Cash flows from operating activities:


Net loss

   $ (14,271   $ (5,848

Adjustments to reconcile net loss to net cash used in
operating activities:


Noncash revenue from equity investments

     (46     (46

Fair value adjustments

     3,079       627  


     877       877  

Stock-based compensation

     1,775       520  

Noncash research and development expenses

     435       —    

Noncash investment accretion

     83       (1

Decrease (increase) in assets:


Accounts receivable, net

     2,404       1,065  

Unbilled and other receivables

     5,154       973  

Reduction in the carrying amount of right of use assets

     1,299       1,311  

Prepaid expenses and other assets

     (1,106     87  

Increase (decrease) in liabilities:


Accounts payable

     2,110       1,028  

Accrued payroll, taxes, and benefits

     (2,289     (685

Deferred revenue

     (3,378     (2,714

Lease liabilities

     (1,266     (1,469

Other accrued liabilities

     (638     (348







Net cash used in operating activities

     (5,778     (4,623







Cash flows from investing activities:


Purchases of property and equipment

     (843     (1,065

Purchases of equity investments

     (2,869     —    

Purchases of marketable securities

     (127,109     (21,337

Proceeds from sale and maturity of marketable securities

     42,908       6,325  







Net cash used in investing activities

     (87,913     (16,077







Cash flows from financing activities:


Issuances of common stock upon initial public offering, net

     212,277       —    

Issuances of Series E preferred stock, net

     —         4,951  

Issuances of common stock upon stock option exercise

     177       115  

Contribution by noncontrolling interest

     —         100  







Net cash provided by financing activities

     212,454       5,166  







Net increase (decrease) in cash and cash equivalents and restricted cash

     118,763       (15,534

Cash and cash equivalents and restricted cash, beginning of period

     26,486       77,716  







Cash and cash equivalents and restricted cash, end of period

   $ 145,249     $ 62,182  







Supplemental disclosure of cash flow and noncash information


Cash paid for income taxes

   $ 64     $ 62  

Supplemental disclosure of non-cash investing and financing activities


Purchases of property and equipment

     254       —    

Acquisitions of right of use assets in exchange for lease obligations

     1,778       149  

Right of use assets recognized on adoption

     —         16,475  

Accrued offering costs

     786       —